benzyl 2-{[(3-benzyloxycarbonylamino-4-t-butoxycarbonylbenzenesulfonylamino)carbonyl]amino}-4-chlorobenzoate | 259537-01-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl 2-{[(3-benzyloxycarbonylamino-4-t-butoxycarbonylbenzenesulfonylamino)carbonyl]amino}-4-chlorobenzoate
• 英文别名: tert-butyl 4-[(5-chloro-2-phenylmethoxycarbonylphenyl)carbamoylsulfamoyl]-2-(phenylmethoxycarbonylamino)benzoate
• CAS: 259537-01-4
• 化学式: C₃₄H₃₂ClN₃O₉S
• 分子量: 694.162
• InChiKey: KWPOMFVSPZZXOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  48
• 可旋转键数：
  14
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  175
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  tert-butyl 4-aminosulfonyl-2-((benzyloxycarbonyl)amino)benzoate 、 benzyl 4-chloro-2-N-phenoxycarbonylanthranilate 以3.74 g (yield 77%) of 2-{[(3-benzyloxycarbonylamino-4-t-butoxycarbonylbenzenesulfonylamino)carbonyl]amino}-4-chlorobenzoic acid benzylester (property: colorless amorphous, PMR (δppm, DMSO-d6): 1.54 (9H, s), 5.19 (2H, s), 5.34 (2H, s), 7.05 (1H, m), 7.34-7.58 (10H, m), 7.60 (1H, d), 7.90 (1H, d), 7.98 (1H, d), 8.50 (1H, br), 8.62 (1H, s), 10.00 (1H, br), 10.41 (1H, s)) was obtained的产率得到benzyl 2-{[(3-benzyloxycarbonylamino-4-t-butoxycarbonylbenzenesulfonylamino)carbonyl]amino}-4-chlorobenzoate
  参考文献：
  名称：

  Blood vessel lipid deposition-preventive agent comprising chymase-inhibitor

  摘要：

  提供一种预防或治疗伴随血管功能异常的疾病的药物，其中涉及血管内脂质沉积，该药物包括一种作为活性成分的Chymase抑制剂。作为Chymase抑制剂，使用下式表示的喹唑啉衍生物。在上述公式中，环A代表芳香环。

  公开号：

  US06921766B1

文献信息

• PREVENTIVE OR THERAPEUTIC DRUGS FOR FIBROSIS CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT
  申请人：——

  公开号：US20020183338A1

  公开（公告）日：2002-12-05

  A medicament for the prevention or treatment containing a chymase inhibitor, as an effective component, which is a side effect-free, safe medicament for prevention or treatment of fibrosis of the skin or various viscera which suppresses the progression of the condition, prevents the progression of complications, and improves the quality of life of the patient, wherein a quinazoline derivative having the formula (I): 1 or a pharmaceutically acceptable salt thereof is included therein.

  一种预防或治疗皮肤或各种内脏纤维化的药物，含有一种作为有效成分的针对钠胃蛋白酶抑制剂，是一种无副作用、安全的药物，可抑制病情的进展，预防并改善并发症的发展，并提高患者的生活质量，其中包括具有以下结构式(I)的喹唑啉衍生物或其药用盐。
• Preventive or therapeutic drugs for various eosinophilia-related diseases containg chymase inhibitors as the active ingredient
  申请人：——

  公开号：US20020187989A1

  公开（公告）日：2002-12-12

  A medicament for the prevention or treatment of diseases involving an increase of eosinophils having a chymase inhibitor, as its effective ingredient, which is a safe medicament for the prevention or treatment of diseases accompanied with an increase in eosinophils, which suppresses the progress of the condition, prevents progress of complications, and improves the quality of life of the patient, wherein a quinazoline derivative having the formula (I): 1 or a pharmaceutically acceptable salt thereof is included.

  这是一种药物，用于预防或治疗涉及嗜酸性粒细胞增多的疾病，其有效成分为一种凝血酶抑制剂，是一种安全的药物，用于预防或治疗伴随嗜酸性粒细胞增多的疾病，可以抑制疾病的进展，防止并发症的进展，并改善患者的生活质量，其中包括具有公式（I）：1的喹唑啉衍生物或其药学上可接受的盐。
• Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient
  申请人：——

  公开号：US20020183339A1

  公开（公告）日：2002-12-05

  A medicament safe and free from side effects, for the prevention or treatment of dermatitis exhibiting a biphasic inflammation reaction or dermatitis induced by repeated exposure to an antigen, which suppresses the progress of the condition and improves the quality of life of the patient, which medicament treats dermatitis exhibiting a biphasic inflammation reaction or dermatitis induced by repeated exposure to an antigen by including a quiazoline derivative having the formula (I) or (II) or its pharmaceutically acceptable salt as an effective ingredient: 1

  一种安全且无副作用的药物，用于预防或治疗表现为双相炎症反应的皮炎或由重复暴露于抗原引起的皮炎，该药物抑制病情进展并改善患者的生活质量，其中包括一种喹唑啉衍生物，其具有公式（I）或（II）或其药学上可接受的盐作为有效成分，用于治疗表现为双相炎症反应的皮炎或由重复暴露于抗原引起的皮炎。
• [EN] QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEROF<br/>[FR] DÉRIVÉS DE LA QUINAZOLINE ET LEURS APPLICATIONS PHARMACEUTIQUES -
  申请人：SUNTORY LTD

  公开号：WO2000010982A1

  公开（公告）日：2000-03-02

  A quinazoline derivative having formula (I), or a pharmaceutically acceptable salt thereof, which has a chymase inhibitory activity and suppresses the exacerbation of vascular permeability induced by chymase and useful as a medicament, and a pharmaceutical composition containing the same as an essential ingredient.

  具有式（I）的喹唑啉衍生物，或其药学上可接受的盐，具有抑制胰蛋白酶活性并抑制胰蛋白酶引起的血管通透性恶化的活性，可用作药物，并含有该物质作为必要成分的制药组合物。
• Quinazoline derivatives and pharmaceutical applications thereof
  申请人：Fukami Harukazu

  公开号：US20050148608A1

  公开（公告）日：2005-07-07

  A quinazoline derivative having formula (1) and a pharmacrutically acceptable salt thereof: wherein the ring A represents an aryl group. which derivative has a chymase inhibitory activity and suppresses the exacerbation of cascular permeability induced by chymase, and a pharmaceutical composition containing the same as an essential ingredient. These compounds are useful for treatment of allergic diseases, rheumatic diseases, and cardiac and circulatory system diseases which are due to the abnormal exacerbation of Angiotensin II production.

  具有公式（1）的喹唑啉衍生物及其药学上可接受的盐：其中环A代表芳基基团。该衍生物具有抑制胰蛋白酶活性并抑制由胰蛋白酶诱导的血管通透性加剧的作用，并包含其作为必要成分的药物组合物。这些化合物对于治疗过敏性疾病、风湿性疾病以及由血管紧张素II产生异常加剧引起的心脏和循环系统疾病非常有用。